BioSpace News Archive

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer reviewed publication of LPCN 144 Liver Fat Study (“LFS”) results, “LPCN 1144 Resolves Non-Alcoholic Fatty Liver Disease In Hypogonadal Males” in Hepatology Communications . Drs. Somaya Albha

- Biohaven’s verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH - Verdiperstat is a brain-penetrant inhibitor of myeloperoxidase (MPO), an enzyme implicated in neuroinflammatory and neurodegenerative disorders including ALS

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August.

GranBio, a 100% Brazilian industrial biotechnology company, and NextChem, Maire Tecnimont’s subsidiary for energy transition announced a strategic partnership to achieve global leadership in the licensing of patented GranBio 2G Ethanol technology to produce cellulosic ethanol.

Otonomy, Inc. announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has been named one of Philadelphia’s “Best Places to Work” for the fourth year in a row by the Philadelphia Business Journal. “In seven years, we have grown to a team of more than 500 employees, who are truly what make Spark T

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020. Management will host a conference call on August 10, 2020 at 8:30 a.m. ET to discuss these results

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 1:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at

VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update. Thursday, August 13 @ 8:30amET From

Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates.